Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.